GlassScriptPhysician profile
Vicky W Yang
NPI 1710063334
$5,912.25
in general payments reported to CMS, 2019-2025
30 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $448 · 2021: $588 · 2022: $761 · 2023: $651 · 2024: $707 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.63 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $806.79 | 2019-2025 | |
| Janssen Biotech, INC. | $711.84 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.11 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $548.79 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $475.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $172.40 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $171.77 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $126.08 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $118.45 | 2019-2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $104.80 | 2019-2023 | Rebyota |
| Echosens North America, INC. | $63.13 | 2025 | Fibroscan |
| Novo Nordisk INC | $59.18 | 2025 | Wegovy |
| Genzyme Corporation | $51.68 | 2023 | |
| Celgene Corporation | $45.04 | 2021-2023 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $40.89 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $38.78 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $36.29 | 2020 | |
| Allergan, INC. | $32.32 | 2019 | |
| Intercept Pharmaceuticals, INC. | $29.97 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $28.65 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.32 | 2023 | Cyltezo |
| Exact Sciences Corporation | $24.85 | 2025 | The Cologuard Plus Collection Kit |
| Acacia Pharma INC | $22.63 | 2021 | |
| Pfizer INC. | $20.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.43 | 2023 | Dupixent |
| Redhill Biopharma INC. | $19.02 | 2020 | |
| Sandoz INC. | $16.71 | 2023 | Hyrimoz |
| Advanced Accelerator Applications | $15.00 | 2019 | |
| Endo Pharmaceuticals INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.